Neuland Labs: Looking Beyond the Quarterly Volatility
Table of Contents
Valuations first: expectations, mean reversion, and margin of safety
Neuland’s transition from API company to embedded CDMO platform
Peptides, capability compounding, and the next phase of growth
Long term story?
Valuations First …
One of the most important things investors need to understand about Neuland is that the market was never valuing the company on trailing earnings alone. When the stock traded at nearly 60x to as high as 80x EV/EBITDA (on a depressed EBITDA of-course), many investors called it irrational. But markets are often forward-looking. The valuation was effectively discounting a future state where Neuland would evolve from a mid-sized API player into a higher-quality CDMO platform with structurally superior margins and stronger cash generation.
That future, at least partially, has now arrived.
FY26 EBITDA margins expanded meaningfully to nearly 30%, while Q4 margins crossed 40% because of business mix, operating leverage, and scale-up of commercial molecules. In simple terms, the market had already anticipated that Neuland’s economics would improve sharply once commercial CDMO projects scaled. In Q4 FY26, Neuland has now delivered on that promise. Expectations have largely been met.
This is where Michael Mauboussin’s framework around expectations becomes useful. Stock prices are not driven purely by business quality. They are driven by the gap between expectations and reality. A great business can still become a poor investment if expectations become excessive. Similarly, an average business can generate excellent returns if expectations are too pessimistic. In Neuland’s case, the market had already embedded very optimistic assumptions around future EBITDA expansion, peptide optionality, and commercial scale-up.
As those expectations begin getting validated, valuation multiples naturally start mean-reverting. That does not necessarily mean the business has weakened. It simply means the market is gradually shifting from “future possibility” pricing towards “delivered performance” pricing.
There is another subtle point here. Businesses that successfully navigate volatility and emerge stronger often deserve premium valuations. Neuland has clearly demonstrated operational resilience. The company handled shipment volatility, customer scaling, and manufacturing complexity while still delivering record profitability. That deserves recognition. But resilience alone does not make valuation irrelevant.
At the current stage, investors need to be careful not to confuse business quality with valuation attractiveness. The stock is no longer cheap on “antifragile measures” like P/S (price-to-sales) or P/B (price-to-book). P/E based valuation lenses are definitely fragile unless it’s a more linear cash flow model such as FMCG. In earlier years, most investors were unwilling to pay high P/S multiple for future optionality. Today, much of that optionality is already recognised by the market.
CDMO valuations look stretched: many firms trade above 15× P/S (Azad Engg ~25×; MTAR similar). The market is signalling either expectations of dramatic sales growth or an impending culling - implying a different risk-reward profile than few years ago.
A useful analogy is a student expected to top the class. If the student performs poorly, the reaction is severe because expectations were high. But even if the student performs exactly as expected, the room for surprise reduces sharply. Future upside then depends on outperforming already elevated expectations, which becomes progressively harder.
